{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"428","value":"1564"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"Mean Cmax (±SD)","dispersionType":"Standard Deviation","groups":[{"description":"Visilizumab, Tacrolimus and Methotrexate. All participants.","id":"OG000","title":"First Study Stage: Study Treatment"}],"paramType":"MEAN","populationDescription":"All participants","reportingStatus":"POSTED","timeFrame":"At 1 - 2 hours","title":"Pharmacodynamics of Visilizumab - Test 1","type":"SECONDARY","unitOfMeasure":"ng/mL"}